Synaffix Aims For Top ADC Tech Provider Spot After Inking MacroGenics Deal
Pact Potentially Worth $586m
The Dutch firm’s dream to become the number one antibody drug conjugate technology provider by 2023 has been bolstered by a flurry of recent strategic collaborations, including one with MacroGenics.
